Articles tagged with Pancreatic Cancer
A novel liquid biopsy technology developed by UCSC Assistant Professor Daniel Kim's lab leverages RNA 'dark matter' to enhance cancer diagnosis. The test detects both protein-coding and repetitive noncoding RNAs in the blood, showing improved sensitivity for early-stage cancer detection.
A new Australian drug, PXS-5505, has shown promise in treating aggressive pancreatic cancer by targeting fibrotic tissue within tumours. The drug combination therapy significantly reduced fibrosis and improved chemotherapy effectiveness, increasing survival time by over 35%.
Patients with cancer who live in rural Pennsylvania counties are more likely to receive complex surgeries at high-volume hospitals due to their perceived better outcomes. However, for less complex surgeries, rural patients are less likely to opt for high-volume hospitals despite potential benefits from centralization.
Benzodiazepine lorazepam is associated with shorter progression-free survival in pancreatic cancer patients. In contrast, alprazolam use was linked to a longer progression-free survival. Lorazepam may activate GPR68, boosting IL-6 expression and promoting tumor growth in the pancreatic microenvironment.
Researchers at Sylvester Comprehensive Cancer Center will investigate signaling mechanisms between myeloid-derived suppressor cells and pro-inflammatory cancer-associated fibroblasts in pancreatic cancer. The goal is to develop a nanoengineered immunotherapy that selectively disrupts these interactions to target treatment resistance.
A large long-term study found that good cardiorespiratory fitness in young men is associated with a significantly lower risk of developing nine specific cancers, including a 40% reduced risk of liver cancer. Higher fitness was also linked to lower risks of rectal, pancreatic, and bowel cancers.
A study published in Nature found no link between the pancreatic microbiome and the development of pancreatic cancer, contradicting earlier findings that suggested a potential method for preventing the disease. The researchers reanalyzed data from an original study and used pancreatic cancer tissue samples to confirm their results.
Researchers aim to treat pancreatic ductal adenocarcinoma by targeting amino acid transporter SLC6A14 and compensatory nutrient scavenging mechanisms autophagy and macropinocytosis. Using alpha-methyl-L-tryptophan and hydroxychlorquine, the study seeks to improve therapeutic outcomes in patients with pancreatic cancer.
Researchers discovered that high blood glucose levels make pancreatic cancer cells more sensitive to chemotherapy, which could lead to improved treatment outcomes. In a mouse model and clinical data, the study found a nearly 40% lower risk of death among patients with elevated glucose levels compared to those with normal levels.
A new combination treatment of GVAX vaccine, nivolumab, and urelemab has shown to increase the amount of cancer-killing immune cells in tumors and appear effective when given two weeks prior to surgery. The study found a median disease-free survival of 33.51 months and a median overall survival of 35.5 months.
Amplified Sciences has received a $400,000 NCI grant to develop and validate an assay testing for the detection of pancreatic cancer in patients diagnosed with pancreatic cystic lesions. The company aims to improve the accuracy of diagnoses, reducing unnecessary surgical interventions.
Researchers at Kumamoto University identified a cell surface marker, ROR1, that promotes hyperproliferation and metastasis in pancreatic cancer. High expression of ROR1 drives tumorigenicity and intratumor heterogeneity, suggesting a potential therapeutic target for pancreatic cancer therapy.
A study found disparities in Hispanic cancer mortality rates, with higher rates for men in certain age groups and women for liver, pancreatic, and uterine cancers. The researchers highlight the need for targeted education and screening efforts to address these disparities.
A Mayo Clinic study reveals that minimally invasive surgical procedure staging laparoscopy can identify cancer spread early and determine the stage of pancreatic cancer. The research found a higher risk of cancer spread in patients with certain factors, such as age and tumor markers.
Researchers at UC San Diego found a novel combination of KRAS and ERBB drug inhibitors outperformed treatments in human and mouse models of pancreatic cancer. The combination reduced drug resistance and increased survival rates.
The study, published in JAMA Oncology, found that the percentage of cancer survivors reporting functional limitations has more than doubled over the past 20 years. The adjusted prevalence of functional limitation was highest among pancreatic and lung cancer survivors, while melanoma survivors had the lowest rate.
Researchers found that only 6.8% of cancer patients underwent genetic testing within two years of diagnosis, with lower rates among Black, Hispanic, and Asian patients. The low rates are attributed to lack of integration of test results into cancer management and prevention.
UMC Utrecht researchers are conducting two new projects to treat cancer using image-guided interventions. One project uses MRI-guided radiotherapy for locally advanced pancreatic cancer, while the other employs ultrasound techniques for head and neck cancers.
Researchers found that distant cancers alter liver function by inducing fat accumulation and inflammation in liver cells. The process involves secretion of extracellular vesicles containing fatty acids, which reprogram the liver to resemble fatty liver disease.
Researchers have discovered that HER3 plays a crucial role in promoting cell survival in metastatic colorectal and pancreatic cancer. The surrounding liver microenvironment activates HER3, making it an emerging therapeutic target for these types of cancer.
Researchers at Michigan Medicine have discovered a new nutrient source that pancreatic cancer cells use to grow in the absence of glucose. Uridine is found in the tumor microenvironment and its exact source remains unknown. Blocking uridine metabolism may lead to new treatment options for pancreatic cancer.
Research reveals both metabolically healthy and unhealthy obesity types linked to increased risk of various obesity-related cancers, with stronger association in metabolically unhealthy obesity. Metabolically unhealthy women face higher risks for endometrial, liver, and kidney cancers.
A new study in mice reveals that pancreatic cancer's emergence is fueled by the expansion of cell-to-cell communication. Researchers found that plasticity and inflammation reshape cells' identities and local environments, fostering cancer growth. The study provides insights into the earliest cellular events leading to PDAC and potentia...
SpaceMarkers, a new machine learning software, can identify molecular interactions among distinct cell types in and around tumors. By analyzing spatial transcriptomics data, it reveals genes overexpressed due to cell-to-cell interactions, providing new avenues for understanding cancer progression and treatment responses.
Scientists have developed a gene-editing technique that allows them to easily engineer specific cancer-linked mutations into mouse models. This new method, based on CRISPR genome-editing technology, enables researchers to explore many unknown mutations and develop new drugs targeting those mutations.
Scientists have identified a specific gene mutation that triggers an inflammatory cascade, driving the development of treatment-resistant cancers. The study reveals a molecular circuitry by which mutations in the STK11 gene cause inflammation to spiral out of control.
An AI tool has identified people at highest risk for pancreatic cancer, suggesting population screening could expedite diagnosis and improve outcomes. The model predicted disease occurrence with accuracy comparable to genetic sequencing tests, targeting those at elevated risk without relying on family history or genetic mutations.
A research tool developed at the Garvan Institute has uncovered unprecedented detail about pancreatic cancer drug response and resistance. The molecule AKT, a key driver of cancer growth and spread, is activated in distinct parts of the tumour, including areas of low oxygen supply where it forms pockets of resistance to therapy.
Researchers at the University of Colorado Cancer Center have made a breakthrough in treating pancreatic cancer by combining radiation and immunotherapy. The treatment eradicates tumors while stopping the cancer from spreading, offering new hope for patients. Clinical trials are planned to further develop this therapy.
Researchers identify SRSF1 as a key player in promoting pancreatitis and pancreatic cancer growth. High levels of SRSF1 are associated with worse patient outcomes, highlighting its potential as a target for new therapies.
Jeong Min Lee, KSR President and professor at Seoul National University Hospital, is honored with ARRS membership. He has published over 470 scientific articles and serves on the editorial board of several publications.
Researchers at UC Irvine have identified key themes in the biology of pancreatic cancer that can serve as hallmarks for therapy. These themes include genomic alterations, metabolism, and immunotherapy, which can be combined to improve treatment outcomes.
Researchers have developed an implantable nanofluidic device that delivers CD40 monoclonal antibodies to shrink pancreatic tumors, reducing treatment dosage by fourfold. The device's long-term controlled release avoids systemic side effects, offering a promising alternative for cancer patients.
Researchers analyzed 30 healthy pancreata from diverse donors and found PanIN lesions in 18 cases, which had distinct microenvironments compared to normal pancreatic tissue. The study suggests that PanINs may already possess features of malignant cells and challenges the long-held assumption that they always progress to cancer.
The University of Texas at El Paso will study the role of obesity and inflammation in pancreatic cancer development, a disease with high mortality rates. The grant aims to develop targeted treatments and preventives, potentially transforming understanding of pancreatic cancer.
A study published in the journal Cancer found that long-term pancreatic cancer survivors have a robust immune response and enriched gut microbiome species, including Faecalibacterium prausnitzii. The research suggests that these bacterial species may promote immune response to pancreas cancer.
A new study of over 200 people with premature aging syndromes caused by abnormally short telomeres suggests that chromosomal instability may not be the reason for increased cancer risk. Instead, immune system cells that age and die prematurely may play a role in cancer predisposition.
Cancer cells have been found to employ a strategy to evade the immune system's killer T cells by interacting with myeloid cells and suppressing type 1 interferon production. This natural pathway is crucial for recruiting killer T cells to combat cancer spread. Researchers hope to develop new therapeutic approaches, such as forcing tumo...
Researchers have found that valosin-containing protein (VCP) is essential for KRAS-mutant pancreatic ductal adenocarcinoma cell growth and survival. Inhibiting VCP, combined with autophagy inhibition, enhances efficacy in preclinical studies.
Sylvester researchers have identified a signaling circuit that instigates immunosuppression and tumor-promoting inflammation in the pancreatic tumor microenvironment, driving treatment resistance. Immature neutrophils are found to play a critical role in this process.
A Duke University research team has identified a set of biomarkers that could help distinguish between cysts on the pancreas that are likely to develop into cancer and those that will remain benign. The findings have significant implications for preventing the development of pancreatic cancer, which is on the rise and is notorious for ...
A new radiotracer successfully detected 100% of primary tumors across multiple cancer types, outperforming the current standard. It also showed promise in detecting lymph node and distant metastases, offering a promising alternative for diagnosis and treatment.
Researchers at Karolinska Institutet discovered an immune cell in women with pancreatic cancer that blocks the immune response, leading to poor survival. The study identifies a specific protein FPR2 as a potential therapeutic target for immunotherapy in women.
Researchers at Garvan Institute of Medical Research found that introducing bacteria to a tumor's microenvironment triggers an immune response, activating neutrophils to destroy tumors in animal models. This breakthrough therapy targets neutrophils to improve cancer treatment outcomes.
Researchers at City University of Hong Kong identified lysyl hydroxylase 1 (LH1) as a key factor in promoting confined migration of liver and pancreatic cancer cells. The study found that LH1 promotes metastasis by stabilizing Septin2, which enhances the actin network.
Lung cancer death rates are projected to decrease overall in the EU and UK in 2023, however, a concerning trend is observed among women in France, Italy, and Spain. Meanwhile, pancreatic cancer death rates are forecasted to rise among women due to continued smoking habits.
The use of AI is improving diagnostic accuracy for digestive cancers, but challenges in data sharing and standardization hinder its widespread application. Researchers surveyed recent applications of AI to these deadly cancers, finding that AI can automate complex processes and detect patterns not visible to humans.
Researchers at VCU Massey Cancer Center found that simultaneous activation of Prdm16 and Smad4 proteins slows down pancreatic cancer progression. The study suggests a novel therapeutic approach to tackle this deadly disease.
A new study found that chemotherapy alters the immune cell landscape in pancreatic cancer, reducing checkpoint molecules and increasing tumor growth. The research suggests that this may lead to resistance to subsequent immunotherapy, highlighting the need for further study on combining chemotherapy with immunotherapy.
A recent study confirms that pancreatic cancer rates are rising faster in women than men, particularly among younger women and Black women. The rate of pancreatic cancer among women under the age of 55 increased by 2.4% compared to men of the same age, highlighting a significant disparity in mortality rates between the sexes.
Researchers explore CEACAM1, CEACAM5, and CEACAM6's pathological significance in cancer biology and immunology. The review highlights their interactions with pathogens and potential avenues for cancer therapy.
Researchers detected high levels of hydrogen peroxide in pancreatic cancer cells, which makes it a critical target for cancer treatment and research. The study also showed that cancer-promoting mutations lead to suppressed genetic expression of enzymes breaking down hydrogen peroxide.
The NCI is funding a $587,000 research grant to improve KRAS treatment resistance in pancreatic cancer. Dr. Andrew Waters aims to develop personalized medicine approaches by studying unique resistance mechanisms.
Researchers found that primary cancer tumors have a sluggish conversion of nutrients to usable cellular energy, conserving energy for growth and metastasis. The discovery has vast implications for anti-cancer strategies, directing attention to slow energy metabolism.
Researchers analyzed tumor microenvironment of pancreatic cancer, revealing two major defects that inhibit immune response. The study suggests a new approach using anti-CD137 agonist antibody treatment in combination with anti-PD-1 immunotherapy to activate T cells.
Researchers at MUSC Hollings Cancer Center discovered the cellular origin of normal pancreatic fibroblasts and cancer-associated fibroblasts, which play a key role in tumor progression. The findings suggest that targeting cancer-associated fibroblasts holds exciting potential for therapeutic benefits.
A Phase 3 clinical trial has shown that a four-drug chemotherapy regimen significantly increases overall survival and progression-free survival in patients with stage 4 pancreatic ductal adenocarcinoma. The study's results suggest that this more aggressive treatment approach may be considered for eligible patients.
Researchers at UC San Diego describe how pancreatic cancer stem cells leverage SMARCD3, a protein that normally suppresses tumors, to boost resistance to treatments and drive growth. Deleting SMARCD3 reduces tumor growth and improves survival rates.
Researchers discovered a molecular pathway critical to the initiation of pancreatic tumors, which can contribute to disease resistance and metastasis. Targeting this pathway could limit tumor progression, relapse, and spread by disrupting the interaction between cancer cells and their microenvironment.
Scientists have found a way to break down the resistance of mice with neuroendocrine pancreatic cancer to checkpoint blockade immunotherapy. A new drug combination, PD1-IL2v and anti-PD-L1, enhances anti-tumor immunity by stimulating specific T cells and reprogramming macrophages, leading to increased survival rates in tumor-bearing mice.